Pricing Log in Create free account
Saturday 17 October 2026 Export QDEL’s income statement to Excel — free account

QuidelOrtho Corporation

QDEL Healthcare Medical Devices

QuidelOrtho Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, down 1.89% from fiscal 2024. In the quarter to June 2026, revenue grew 2.77%, EPS grew 63.9%, free cash flow fell 61.5% and total debt rose 10.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

12.94 0.97 −6.97%
Market cap
$953.9M
P/E
0.0×
Fwd P/E
−9.0×
Dividend yield
—
F-score
6/9
Altman Z
0.11
Beneish M
−3.12
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.25
Total sells 0.11
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 4 1 — 3 — — — — — — — —
Sell 1 — — — — — — — — — — —
Insider Ownership 0.50%

Capital & Financial Ratios $m

Market Cap 953.88
Revenue 2,674.20
Net Income (1,048.40)
Free Cash Flow (211.20)
Net Debt 2,767.70
Current Ratio 1.39
Debt/Equity 1.63
P/E ratio 0.00
Fwd P/E (8.96) (negative: loss-making)
P/S ratio 0.33
P/B ratio 0.50
Past 5Y EPS Growth —
This Y EPS Growth (63.61%) (below 0%: weak)
Next Y EPS Growth 85.11% (at or above 15%: strong)
Next Y revenue growth (6.82%) (below 0%: weak)
Next 5Y EPS Growth (4.59%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.4×, against a ten-year median of 2.8×; over the ten years it ranged from 1.2× in 2022 to 18.3× in 2020.
P/S against its own 10 years 2.03%
10-year low 10-year high
P/B against its own 10 years 2.29%
10-year low 10-year high
EV/Sales against its own 10 years 4.98%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 167 98 170 123
Receivables 303 282 417 352
Inventory 578 534 578 619
Other — 42 32 32
1,311 1,219 1,447 1,377
2023 2024 2025 Q'26
Payables 295 246 279 237
ST’ Debt 140 342 178 356
Other 303 289 377 310
834 999 966 993

Compound Annual Growth %

10y 5y 3y
Sales 30.13% 10.44% (5.80%)
Cash Flow 11.05% (30.08%) (50.84%)
Earnings 0.00% 0.00% 0.00%
Book Value 24.27% 7.58% (26.99%)

Revenue $m

Mar Jun Sep Dec Year
’26 620 631 — — —
’25 693 614 700 724 2,730
’24 711 637 727 708 2,783
’23 846 665 744 743 2,998
’22 1,002 613 784 866 3,266
’21 375 177 510 637 1,699
’20 175 202 476 809 1,662
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (33) (111) — — —
’25 66 (47) (45) 132 105
’24 (1) (98) 118 64 83
’23 189 (31) 42 80 280
’22 501 225 (10) 169 885
’21 585 (178) 77 321 806
’20 61 59 70 439 630
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (67) (136) — — —
’25 9 (84) (95) 87 (83)
’24 (67) (133) 71 26 (103)
’23 123 (82) (2) 32 71
’22 478 199 (40) 108 744
’21 507 (253) (30) 289 513
’20 55 51 48 410 565
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (1.35) (1.36) — — —
’25 (0.19) (3.77) (10.78) (1.92) (16.69)
’24 (25.50) (2.20) (0.30) (2.28) (30.16)
’23 0.73 (0.80) (0.19) 0.10 (0.15)
’22 11.31 0.36 0.28 0.45 9.56
’21 4.09 0.45 5.08 6.85 16.43
’20 0.93 1.55 5.33 10.78 18.60
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 13.21 18.25 41.50 46.71 71.90 103.31 66.88 57.54 29.74 19.50

Analyst estimates 2026–2028

Powerpack
High 23.94 46.14 77.63 75.18 306.72 265.00 135.90 98.67 75.82 49.45
People
People Employees 627 1,193 1,224 1,250 1,370 1,600 7,000 7,100 6,600 6,500
Revenue/emp, $m 0.31 0.23 0.43 0.43 1.21 1.06 0.47 0.42 0.42 0.42
Income, $m
Income, $m Revenue 192 278 522 535 1,662 1,699 3,266 2,998 2,783 2,730
Gross margin, % 58.31 56.22 60.45 59.98 81.62 75.26 59.28 49.94 46.23 46.67
EBT (16) (8) 63 77 1,040 900 736 (29) (2,131) (1,108)
EBT margin, % (8.45) (2.89) 12.14 14.43 62.60 53.00 22.53 (0.97) (76.59) (40.57)
Net income (14) (8) 74 73 810 704 549 (10) (2,052) (1,132)
Depreciation 29 39 60 58 49 53 284 457 2,276 1,143
Per share, $
Per share, $ Revenue 5.86 8.23 13.75 13.09 39.47 40.35 57.50 44.88 41.41 40.27
Earnings (0.42) (0.24) 1.95 1.78 19.24 16.74 9.66 (0.15) (30.16) (16.69)
Cash flow 0.36 0.82 3.59 3.29 14.96 19.14 15.59 4.19 1.24 1.55
Capex (0.36) (0.52) (0.83) (0.67) (1.54) (6.95) (2.48) (3.13) (2.76) (2.78)
Free cash flow 0.00 0.30 2.75 2.63 13.42 12.19 13.11 1.06 (1.53) (1.22)
Book value 6.13 6.73 11.20 13.70 31.66 45.83 86.88 74.94 44.41 28.33
Shares, m 33 34 38 41 42 42 57 67 67 68
Valuation, ×
Valuation, × P/E 0.00 0.00 24.66 42.15 9.34 8.04 6.76 0.00 0.00 0.00
P/S 3.56 5.40 3.55 5.73 4.55 3.35 1.48 1.67 1.08 0.71
P/B 3.40 6.60 4.36 5.48 5.68 2.95 0.98 1.00 1.00 1.01
EV/Sales 3.43 6.70 3.58 5.85 4.32 2.86 2.18 2.41 1.93 1.62
EV/FCF (1,307.70) 190.01 17.95 29.30 12.73 9.47 9.57 102.70 (52.11) (52.95)
Cash, $m
Cash, $m Operating cash flow 12 28 136 134 630 806 885 280 83 105
Capex (12) (18) (32) (27) (65) (293) (141) (209) (186) (188)
Free cash flow 0 10 105 107 565 513 744 71 (103) (83)
Balance, $m
Balance, $m Working capital 192 203 34 96 805 1,117 568 477 220 481
Total debt 144 397 107 118 113 1 2,638 2,415 2,483 2,650
Net debt (25) 361 63 65 (377) (828) 2,293 2,247 2,385 2,480
Shareholders’ equity 201 227 426 560 1,333 1,929 4,935 5,006 2,985 1,921
Returns, %
Returns, % ROA (3.47) (1.23) 8.52 8.49 58.25 32.74 9.72 (0.12) (27.38) (18.56)
ROIC (1.58) 1.01 12.26 9.27 69.34 51.40 7.30 1.20 (22.83) (13.05)
ROE (6.59) (3.82) 22.73 14.80 85.63 43.17 15.99 (0.20) (51.36) (46.15)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

QuidelOrtho Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AORT Artivion, Inc. $1.1B — (loss-making) 142× +11.32% (above 0%: growing) n/m −202.47% (below 0%: shrinking) 64.03% (6.65%) Compare
CBLL CeriBell, Inc. $1.1B — (loss-making) — (loss-making) +32.54% (above 0%: growing) n/m −68.63% (below 0%: shrinking) 92.32% (71.11%) Compare
IART Integra LifeSciences Holdings Corporation $1.1B — (loss-making) 26.1× +0.76% (above 0%: growing) n/m +193.48% (above 0%: growing) 52.47% 4.61% Compare
LMRI Lumexa Imaging Holdings, Inc. $1.0B — (loss-making) 14.2× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
PRCT PROCEPT BioRobotics Corporation $1.0B — (loss-making) — (loss-making) +19.34% (above 0%: growing) n/m −24.43% (below 0%: shrinking) 66.01% (28.98%) Compare
QDEL QuidelOrtho Corporation $953.9M — (loss-making) — (loss-making) +2.77% (above 0%: growing) n/m −61.45% (below 0%: shrinking) 43.26% (3.46%)
BBNX Beta Bionics, Inc. $933.8M — (loss-making) — (loss-making) +37.76% (above 0%: growing) n/m −1.87% (below 0%: shrinking) 59.04% (79.90%) Compare
SIBN SiBone $892.3M — (loss-making) — (loss-making) +15.18% (above 0%: growing) n/m +60.12% (above 0%: growing) 79.54% (8.58%) Compare
AHCO AdaptHealth Corp. $871.2M — (loss-making) 13.2× +12.66% (above 0%: growing) n/m −128.56% (below 0%: shrinking) 14.08% (18.61%) Compare
Median of peers $1.0B — 20.2× +13.92% — −13.15% 61.54% (13.59%)

All 149 Medical Devices stocks →

QuidelOrtho Corporation (QDEL) key facts

  • Concern: QuidelOrtho Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, down 1.89% from fiscal 2024.
  • QuidelOrtho Corporation (QDEL) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, QDEL traded at $12.94, a market capitalization of $953.9 million.
  • Return on equity was −46.2% and debt-to-equity 1.63.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 0.11 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

QuidelOrtho Corporation (QDEL) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/QDEL · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com